FASN and metabolic dysfunction-associated steatohepatitis: A preclinical study suggests that TVB3664, a novel FASN inhibitor, significantly ameliorates the fatty liver phenotype, although TVB3664 monotherapy shows moderate efficacy in metabolic dysfunction-associated steatohepatitis (MASH)-related murine HCCs110.